InvestorsHub Logo
Followers 2
Posts 79
Boards Moderated 0
Alias Born 06/23/2014

Re: None

Thursday, 03/02/2017 5:29:27 AM

Thursday, March 02, 2017 5:29:27 AM

Post# of 240
Next week presentation on Keystone symposia:

THURSDAY, MARCH 9

Ethan Emberley, Calithera Biosciences, USA
Short Talk: CB-839, a Selective Glutaminase Inhibitor, has Anti-Tumor Activity in Renal Cell Carcinoma and Synergizes with Everolimus and Cabozantinib

program